Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Motus GI Holdings, Inc is a diagnostics & research business based in the US. Motus GI shares (MOTS) are listed on the NASDAQ and all prices are listed in US Dollars. Motus GI employs 49 staff and has a trailing 12-month revenue of around USD$161,000.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$1.08 |
---|---|
52-week range | USD$0.46 - USD$2.42 |
50-day moving average | USD$0.9959 |
200-day moving average | USD$1.0182 |
Wall St. target price | USD$2.5 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.213 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.08 from 2021-01-11
1 week (2021-01-08) | 1.89% |
---|---|
1 month (2020-12-15) | 4.35% |
3 months (2020-10-15) | 14.89% |
6 months (2020-07-15) | -8.47% |
1 year (2020-01-15) | -52.42% |
---|---|
2 years (2019-01-15) | -74.35% |
3 years (2018-01-12) | N/A |
5 years (2016-01-12) | N/A |
Revenue TTM | USD$161,000 |
---|---|
Gross profit TTM | USD$-29,000 |
Return on assets TTM | -44.77% |
Return on equity TTM | -107.79% |
Profit margin | 0% |
Book value | $0.466 |
Market capitalisation | USD$34.8 million |
TTM: trailing 12 months
There are currently 451,178 Motus GI shares held short by investors – that's known as Motus GI's "short interest". This figure is 3.3% up from 436,718 last month.
There are a few different ways that this level of interest in shorting Motus GI shares can be evaluated.
Motus GI's "short interest ratio" (SIR) is the quantity of Motus GI shares currently shorted divided by the average quantity of Motus GI shares traded daily (recently around 379141.17647059). Motus GI's SIR currently stands at 1.19. In other words for every 100,000 Motus GI shares traded daily on the market, roughly 1190 shares are currently held short.
However Motus GI's short interest can also be evaluated against the total number of Motus GI shares, or, against the total number of tradable Motus GI shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Motus GI's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Motus GI shares in existence, roughly 10 shares are currently held short) or 0.0189% of the tradable shares (for every 100,000 tradable Motus GI shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Motus GI.
Find out more about how you can short Motus GI stock.
We're not expecting Motus GI to pay a dividend over the next 12 months.
Over the last 12 months, Motus GI's shares have ranged in value from as little as $0.46 up to $2.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Motus GI's is 2.7904. This would suggest that Motus GI's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Motus GI Holdings, Inc., a medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions in the United States and Israel. Its flagship product is the Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The company is based in Fort Lauderdale, Florida.
Steps to owning and managing SCWX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RMAX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTLR, with 24-hour and historical pricing before you buy.
Steps to owning and managing NX, with 24-hour and historical pricing before you buy.
Steps to owning and managing PCH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBPB, with 24-hour and historical pricing before you buy.
Steps to owning and managing PWOD, with 24-hour and historical pricing before you buy.
Steps to owning and managing PZG, with 24-hour and historical pricing before you buy.
Steps to owning and managing OSMT, with 24-hour and historical pricing before you buy.
Steps to owning and managing SEED, with 24-hour and historical pricing before you buy.